Effect of MPA or imatinib on cell growth in Bcr-Abl-positive and −negative cell lines
Cell lines . | Description . | Incubation time (hrs) . | IC50 MPA (μM) . | IC50 imatinib (μM) . |
|---|---|---|---|---|
| 32D-vector | Murine myeloid | 24 | 0.46 (±0.16) | >8 |
| 32D-p185 | Murine myeloid (p 185 Bcr-Abl) | 24 | 0.56 (± 0.14) | 0.56 (± 0.08) |
| FL5.12-vector | Murine pre-B | 24 | 0.4 (± 0.16) | >8 |
| FL5.12-p185 | Murine pre-B (p185 Bcr-Abl) | 24 | 0.8 (± 0.14) | 0.68 (± 0.2) |
| K562 | Human CML (p210 Bcr-Abl) | 72 | 0.41 (± 0.17) | 0.53 (± 0.07) |
| LAMA84 | Human CML (p210 Bcr-Abl) | 48 | 0.47 (± 0.03) | 0.089 (± 0.01) |
| HL-60 | Human promyelocytic leukemia | 48 | 1.0 (± 0.2) | >8 |
| U937 | Human monocytic leukemia | 48 | 0.65 (± 0.37) | >8 |
Cell lines . | Description . | Incubation time (hrs) . | IC50 MPA (μM) . | IC50 imatinib (μM) . |
|---|---|---|---|---|
| 32D-vector | Murine myeloid | 24 | 0.46 (±0.16) | >8 |
| 32D-p185 | Murine myeloid (p 185 Bcr-Abl) | 24 | 0.56 (± 0.14) | 0.56 (± 0.08) |
| FL5.12-vector | Murine pre-B | 24 | 0.4 (± 0.16) | >8 |
| FL5.12-p185 | Murine pre-B (p185 Bcr-Abl) | 24 | 0.8 (± 0.14) | 0.68 (± 0.2) |
| K562 | Human CML (p210 Bcr-Abl) | 72 | 0.41 (± 0.17) | 0.53 (± 0.07) |
| LAMA84 | Human CML (p210 Bcr-Abl) | 48 | 0.47 (± 0.03) | 0.089 (± 0.01) |
| HL-60 | Human promyelocytic leukemia | 48 | 1.0 (± 0.2) | >8 |
| U937 | Human monocytic leukemia | 48 | 0.65 (± 0.37) | >8 |
IC50 values were obtained using the MTT assays. Values represent the mean ± SD for at least 3 experiments.